HRP20191933T1 - Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju - Google Patents
Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju Download PDFInfo
- Publication number
- HRP20191933T1 HRP20191933T1 HRP20191933TT HRP20191933T HRP20191933T1 HR P20191933 T1 HRP20191933 T1 HR P20191933T1 HR P20191933T T HRP20191933T T HR P20191933TT HR P20191933 T HRP20191933 T HR P20191933T HR P20191933 T1 HRP20191933 T1 HR P20191933T1
- Authority
- HR
- Croatia
- Prior art keywords
- combination
- use according
- antibody
- cd16a
- seq
- Prior art date
Links
- 230000003042 antagnostic effect Effects 0.000 title claims 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 claims 5
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 4
- 230000008595 infiltration Effects 0.000 claims 3
- 238000001764 infiltration Methods 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 230000015788 innate immune response Effects 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 229940126546 immune checkpoint molecule Drugs 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Kombinacija (i) multifunkcionalnog antitijela specifičnog za CD30 i CD16A i (ii) antagonističkog anti-PD-1 antitijela, za uporabu u postupku za liječenje CD30+ limfoma.
2. Kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time, što se kombinacija koristi u postupku za povećanje urođenog imunološkog odgovora u usporedbi s odgovorom koji osigurava samo multifunkcionalno antitijelo specifično za CD30 i CD16A.
3. Kombinacija za uporabu u skladu s patentnim zahtjevom 2, naznačena time, što povećani urođeni imunološki odgovor predstavlja povećanu intratumorsku staničnu infiltraciju stanica urođenog imuniteta u tumor.
4. Kombinacija za uporabu u skladu s patentnim zahtjevom 3, naznačena time, što se intratumorska infiltracija makrofaga, dendritskim stanicama i NK-stanicama povećava.
5. Kombinacija za uporabu u skladu s patentnim zahtjevom 4, naznačena time, što se dalje povećava intratumorska infiltracija CD4+ i CD8+ T-stanicama.
6. Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, što je limfom Hodgkinov limfom.
7. Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time, što multifunkcionalno antitijelo sadrži anti-CD30 vezujuću domenu i navedena anti-CD30 vezujuća domena sadrži varijabilnu domenu teškog lanca prikazanu u sekvenci SEQ ID NO:2 i varijabilna domena lakog lanca prikazana u sekvenci SEQ ID NO:3
8. Kombinacija za uporabu u skladu s bilo kojem od patentnih zahtjeva 1 do 7, naznačena time, što multifunkcionalno antitijelo sadrži anti-CD16A vezujuću domenu i navedena anti-CD16A vezujuća domena sadrži varijabilnu domenu teškog lanca prikazanu u sekvenci SEQ ID NO:4 i varijabilnu domenu lakog lanca prikazanu u sekvenci SEQ ID NO:5
9. Kombinacija za uporabu u skladu s bilo kojem od patentnih zahtjeva 1 do 8, naznačena time, što je multifunkcionalno antitijelo bispecifično anti-CD30/CD16A tandemsko diatijelo.
10. Kombinacija za uporabu u skladu s patentnim zahtjevom 9, naznačena time, što bispecifično anti-CD30/CD16A tandemsko diatijelo ima aminokiselinsku sekvencu kao što je prikazano u sekvenci SEQ ID NO:1.
11. Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-10, koja sadrži dodatnu tvar koja modulira molekulu imunološke kontrolne točke odabranu iz grupe antitijela koja se sastoji od anti-CD137 antitijela i anti-CTLA-4 antitijela.
12. Kombinacija za uporabu u skladu s patentnim zahtjevom 11, koja sadrži multifunkcionalno antitijelo specifično za CD30 i CD16A, anti-CD137 antitijelo i anti-PD-1 antitijelo.
13. Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačena time, što se multifunkcionalno antitijelo primjenjuje prije anti-PD-1 antitijela.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166303.6A EP3091031A1 (en) | 2015-05-04 | 2015-05-04 | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor |
| EP16152650 | 2016-01-25 | ||
| EP16723968.0A EP3292153B1 (en) | 2015-05-04 | 2016-05-04 | Combination of a cd30xcd16a antibody with an anti-pd-1 antagonistic antibody for therapy |
| PCT/EP2016/060113 WO2016177846A1 (en) | 2015-05-04 | 2016-05-04 | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191933T1 true HRP20191933T1 (hr) | 2020-01-10 |
Family
ID=56026814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191933TT HRP20191933T1 (hr) | 2015-05-04 | 2019-10-23 | Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11167029B2 (hr) |
| EP (1) | EP3292153B1 (hr) |
| JP (1) | JP6609784B2 (hr) |
| CN (1) | CN107847587B (hr) |
| AU (1) | AU2016257334B2 (hr) |
| BR (1) | BR112017023579A2 (hr) |
| CA (2) | CA2983706C (hr) |
| CY (1) | CY1122283T1 (hr) |
| DK (1) | DK3292153T3 (hr) |
| ES (1) | ES2754557T3 (hr) |
| HK (1) | HK1253022A1 (hr) |
| HR (1) | HRP20191933T1 (hr) |
| HU (1) | HUE045866T2 (hr) |
| LT (1) | LT3292153T (hr) |
| PL (1) | PL3292153T3 (hr) |
| PT (1) | PT3292153T (hr) |
| RS (1) | RS59489B1 (hr) |
| RU (1) | RU2761352C2 (hr) |
| SI (1) | SI3292153T1 (hr) |
| WO (1) | WO2016177846A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018228719B2 (en) | 2017-02-28 | 2023-03-30 | Affimed Gmbh | Tandem diabody for CD16A-directed NK-cell engagement |
| BR112019017869A2 (pt) | 2017-02-28 | 2020-05-12 | Affimed Gmbh | Combinação de um anticorpo anti-cd16a com uma citocina |
| CN109706163A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用 |
| CN109706164A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用 |
| CN111971090B (zh) * | 2018-03-14 | 2024-02-23 | 阿菲姆德股份有限公司 | 双特异性egfr/cd16抗原结合蛋白 |
| BR112020020828A2 (pt) * | 2018-04-13 | 2021-01-19 | Affimed Gmbh | Proteínas de ligação, composições farmacêuticas, método para o tratamento ou melhoria de uma doença, para tratar e/ou prevenir uma doença, para tratar um paciente e para tratar câncer e anticorpos |
| AU2019327155A1 (en) * | 2018-08-27 | 2021-03-18 | Affimed Gmbh | Cryopreserved NK cells preloaded with an antibody construct |
| CN109402168A (zh) * | 2018-10-30 | 2019-03-01 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用 |
| MX2021015411A (es) * | 2019-06-11 | 2022-04-18 | Myeloid Therapeutics Inc | Composiciones acopladoras especificas de macrofagos y metodos de uso de las mismas. |
| AU2020414409A1 (en) * | 2019-12-27 | 2022-06-16 | Affimed Gmbh | Method for the production of bispecific FcyRIIl x CD30 antibody construct |
| CN117580865A (zh) | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | Cd16抗体及其应用 |
| CN118414353A (zh) | 2021-10-08 | 2024-07-30 | 根马布股份公司 | 与cd30和cd3结合的抗体 |
| WO2023080895A1 (en) * | 2021-11-04 | 2023-05-11 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and multispecific engagers |
| AU2022380926A1 (en) * | 2021-11-04 | 2024-05-30 | Affimed Gmbh | Treatment of cancer with nk cells and multispecific engagers |
| CN116059348A (zh) * | 2022-09-16 | 2023-05-05 | 四川大学华西医院 | 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用 |
| CN117442721B (zh) * | 2023-12-20 | 2024-03-15 | 苏州艾凯利元生物科技有限公司 | 一种包括nk细胞和nk细胞接合器分子的组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| EP2397155B1 (en) * | 2005-06-08 | 2017-12-13 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2016029073A2 (en) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
-
2016
- 2016-05-04 BR BR112017023579A patent/BR112017023579A2/pt active Search and Examination
- 2016-05-04 RU RU2017137251A patent/RU2761352C2/ru active
- 2016-05-04 CA CA2983706A patent/CA2983706C/en active Active
- 2016-05-04 WO PCT/EP2016/060113 patent/WO2016177846A1/en active Application Filing
- 2016-05-04 AU AU2016257334A patent/AU2016257334B2/en active Active
- 2016-05-04 DK DK16723968.0T patent/DK3292153T3/da active
- 2016-05-04 CA CA3219372A patent/CA3219372A1/en active Pending
- 2016-05-04 SI SI201630463T patent/SI3292153T1/sl unknown
- 2016-05-04 JP JP2017557405A patent/JP6609784B2/ja active Active
- 2016-05-04 RS RS20191372A patent/RS59489B1/sr unknown
- 2016-05-04 HU HUE16723968A patent/HUE045866T2/hu unknown
- 2016-05-04 EP EP16723968.0A patent/EP3292153B1/en active Active
- 2016-05-04 PL PL16723968T patent/PL3292153T3/pl unknown
- 2016-05-04 PT PT167239680T patent/PT3292153T/pt unknown
- 2016-05-04 CN CN201680026411.5A patent/CN107847587B/zh active Active
- 2016-05-04 LT LT16723968T patent/LT3292153T/lt unknown
- 2016-05-04 ES ES16723968T patent/ES2754557T3/es active Active
-
2017
- 2017-10-19 US US15/788,177 patent/US11167029B2/en active Active
-
2018
- 2018-09-27 HK HK18112399.2A patent/HK1253022A1/zh unknown
-
2019
- 2019-10-23 HR HRP20191933TT patent/HRP20191933T1/hr unknown
- 2019-10-25 CY CY20191101115T patent/CY1122283T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2761352C2 (ru) | 2021-12-07 |
| RU2017137251A (ru) | 2019-06-04 |
| US11167029B2 (en) | 2021-11-09 |
| PL3292153T3 (pl) | 2020-02-28 |
| HUE045866T2 (hu) | 2020-01-28 |
| US20180085456A1 (en) | 2018-03-29 |
| CA2983706C (en) | 2024-01-02 |
| SI3292153T1 (sl) | 2020-01-31 |
| RU2017137251A3 (hr) | 2019-10-10 |
| LT3292153T (lt) | 2019-11-11 |
| JP2018514576A (ja) | 2018-06-07 |
| EP3292153B1 (en) | 2019-07-31 |
| DK3292153T3 (da) | 2019-10-21 |
| BR112017023579A2 (pt) | 2018-07-24 |
| CA3219372A1 (en) | 2016-11-10 |
| AU2016257334B2 (en) | 2021-08-12 |
| CN107847587A (zh) | 2018-03-27 |
| EP3292153A1 (en) | 2018-03-14 |
| WO2016177846A1 (en) | 2016-11-10 |
| JP6609784B2 (ja) | 2019-11-27 |
| AU2016257334A1 (en) | 2017-11-09 |
| HK1253022A1 (zh) | 2019-06-06 |
| ES2754557T3 (es) | 2020-04-20 |
| CA2983706A1 (en) | 2016-11-10 |
| RS59489B1 (sr) | 2019-12-31 |
| CN107847587B (zh) | 2020-10-09 |
| CY1122283T1 (el) | 2020-11-25 |
| PT3292153T (pt) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191933T1 (hr) | Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju | |
| JP2018514576A5 (hr) | ||
| CY1124190T1 (el) | Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση | |
| PH12017502129A1 (en) | Antibodies against ox40 and uses thereof | |
| EA201991632A1 (ru) | Комбинация антитела против cd16a с цитокином | |
| HRP20202024T1 (hr) | Cd3-vežuća domena | |
| PH12016502267A1 (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof | |
| PH12018500363A1 (en) | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof | |
| MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
| GEP20227419B (en) | Pd-1-binding molecules and methods of use thereof | |
| MX2018006072A (es) | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. | |
| EA201791313A1 (ru) | Агенты, связывающие суперсемейство рецепторов фактора некроза опухоли (tnfrsf), и их применения | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| HRP20221284T1 (hr) | Anti-pvrig antitijela i postupci uporabe | |
| EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
| EA202191751A1 (ru) | Гуманизированное антитело против pd-1 человека | |
| GEP201706794B (en) | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof | |
| NZ629816A (en) | Therapeutic peptides | |
| EA201991729A1 (ru) | Антитела к tgf-бета и их применение | |
| PH12014502754A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
| EA201892440A1 (ru) | Антитела к tl1a и их применения | |
| PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
| EP4268848A3 (en) | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy | |
| EA201792460A1 (ru) | Связывающие tigit агенты и варианты их применения |